menu
    • menu
    [{"orgOrder":0,"company":"Xynomic Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Abexinostat","moa":"Histone deacetylase","graph1":"Oncology","graph2":"Phase II","graph3":"Xynomic Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Xynomic Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Xynomic Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Xynomic Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Abexinostat","moa":"Histone deacetylase","graph1":"Oncology","graph2":"Phase II","graph3":"Xynomic Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Xynomic Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Xynomic Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Xynomic Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Abexinostat","moa":"Histone deacetylase","graph1":"Oncology","graph2":"Phase II","graph3":"Xynomic Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Xynomic Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Xynomic Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Xynomic Pharmaceuticals","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Abexinostat","moa":"Histone deacetylase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Xynomic Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Xynomic Pharmaceuticals \/ Cancer Institute and Hospital, Chinese Academy of Medical Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Xynomic Pharmaceuticals \/ Cancer Institute and Hospital, Chinese Academy of Medical Sciences"},{"orgOrder":0,"company":"Pamela Munster","sponsor":"Pharmacyclics | Novartis Pharmaceuticals Corporation | Xynomic Pharmaceuticals, Inc. | GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Abexinostat","moa":"Histone deacetylase","graph1":"Oncology","graph2":"Phase I","graph3":"Pamela Munster","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pamela Munster \/ Pharmacyclics | Novartis Pharmaceuticals Corporation | Xynomic Pharmaceuticals, Inc. | GSK","highestDevelopmentStatusID":"6","companyTruncated":"Pamela Munster \/ Pharmacyclics | Novartis Pharmaceuticals Corporation | Xynomic Pharmaceuticals, Inc. | GSK"},{"orgOrder":0,"company":"University of Nebraska","sponsor":"Xynomic Pharmaceuticals, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Abexinostat","moa":"Histone deacetylase","graph1":"Oncology","graph2":"Phase I","graph3":"University of Nebraska","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Nebraska \/ Xynomic Pharmaceuticals, Inc.","highestDevelopmentStatusID":"6","companyTruncated":"University of Nebraska \/ Xynomic Pharmaceuticals, Inc."},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Abexinostat","moa":"Histone deacetylase","graph1":"Oncology","graph2":"Phase I","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmacyclics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pharmacyclics \/ Undisclosed"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Johnson & Johnson Innovative Medicine | Xynomic Pharmaceuticals, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Abexinostat","moa":"Histone deacetylase","graph1":"Oncology","graph2":"Phase I","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Johnson & Johnson Innovative Medicine | Xynomic Pharmaceuticals, Inc.","highestDevelopmentStatusID":"6","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Johnson & Johnson Innovative Medicine | Xynomic Pharmaceuticals, Inc."},{"orgOrder":0,"company":"Rahul Aggarwal","sponsor":"Xynomic Pharmaceuticals, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Abexinostat","moa":"Histone deacetylase","graph1":"Oncology","graph2":"Phase I","graph3":"Rahul Aggarwal","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rahul Aggarwal \/ Xynomic Pharmaceuticals, Inc.","highestDevelopmentStatusID":"6","companyTruncated":"Rahul Aggarwal \/ Xynomic Pharmaceuticals, Inc."}]

    Find Clinical Drug Pipeline Developments & Deals for Abexinostat

    Menu

    Abexinostat

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Pharmacyclics

                            U.S.A
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Abexinostat

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Safety and Tolerability Study of PCI-24781 in Subjects With Cancer

                            Details : Abexinostat is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Lymphoma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 23, 2010

                            Lead Product(s) : Abexinostat

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie company banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            University of Nebraska

                            Country arrow
                            OTS 2025
                            Not Confirmed

                            University of Nebraska

                            Country arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Abexinostat

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Xynomic Pharmaceuticals, Inc.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma

                            Details : Abexinostat is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Glioma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 26, 2023

                            Lead Product(s) : Abexinostat

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Xynomic Pharmaceuticals, Inc.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Xynomic Pharmaceuticals

                            China arrow
                            OTS 2025
                            Not Confirmed

                            Xynomic Pharmaceuticals

                            China arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Abexinostat

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Cancer Institute and Hospital, Chinese Academy of Medical Sciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Clinical Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Abexinostat in Chinese Patients

                            Details : Abexinostat is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Lymphoma, Non-Hodgkin.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 18, 2019

                            Lead Product(s) : Abexinostat

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Cancer Institute and Hospital, Chinese Academy of Medical Sciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Memorial Sloan Kettering Cancer Center

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Memorial Sloan Kettering Cancer Center

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Abexinostat

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Johnson & Johnson Innovative Medicine | Xynomic Pharmaceuticals, Inc.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma

                            Details : Abexinostat is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Lymphoma, Large B-Cell, Diffuse.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 06, 2019

                            Lead Product(s) : Abexinostat

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Johnson & Johnson Innovative Medicine | Xynomic Pharmaceuticals, Inc.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Xynomic Pharmaceuticals

                            China arrow
                            OTS 2025
                            Not Confirmed

                            Xynomic Pharmaceuticals

                            China arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Abexinostat

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Larg...

                            Details : Abexinostat is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Lymphoma, Large B-Cell, Diffuse.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 03, 2019

                            Lead Product(s) : Abexinostat

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Xynomic Pharmaceuticals

                            China arrow
                            OTS 2025
                            Not Confirmed

                            Xynomic Pharmaceuticals

                            China arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Abexinostat

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients Wi...

                            Details : Abexinostat is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Lymphoma, Follicular.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 02, 2019

                            Lead Product(s) : Abexinostat

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Xynomic Pharmaceuticals

                            China arrow
                            OTS 2025
                            Not Confirmed

                            Xynomic Pharmaceuticals

                            China arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Abexinostat

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma

                            Details : Abexinostat is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Lymphoma, Follicular.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 26, 2018

                            Lead Product(s) : Abexinostat

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Rahul Aggarwal

                            Country arrow
                            OTS 2025
                            Not Confirmed

                            Rahul Aggarwal

                            Country arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Abexinostat

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Xynomic Pharmaceuticals, Inc.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies

                            Details : Abexinostat is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Melanoma, Cutaneous Malignant.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 18, 2018

                            Lead Product(s) : Abexinostat

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Xynomic Pharmaceuticals, Inc.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Pamela Munster

                            Country arrow
                            OTS 2025
                            Not Confirmed

                            Pamela Munster

                            Country arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Abexinostat

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Pharmacyclics | Novartis Pharmaceuticals Corporation | Xynomic Pharmaceuticals, Inc. | GSK

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors

                            Details : PZP115891 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 05, 2012

                            Lead Product(s) : Abexinostat

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Pharmacyclics | Novartis Pharmaceuticals Corporation | Xynomic Pharmaceuticals, Inc. | GSK

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth